Citadel Advisors’s Enzo Biochem, Inc. ENZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-210,877
| Closed | -$78K | – | 15767 |
|
|
2025
Q1 | $78K | Buy |
210,877
+164,921
| +359% | +$91.1K | ﹤0.01% | 11791 |
|
|
2024
Q4 | $32.8K | Buy |
45,956
+19,362
| +73% | +$20.1K | ﹤0.01% | 12786 |
|
|
2024
Q3 | $29.8K | Buy |
+26,594
| New | +$29.8K | ﹤0.01% | 12449 |
|
|
2023
Q4 | – | Sell |
-7,334
| Closed | -$10.3K | – | 15440 |
|
|
2023
Q3 | $10.3K | Buy |
7,334
+1,288
| +21% | +$1.94K | ﹤0.01% | 13075 |
|
|
2023
Q2 | $11.1K | Sell |
6,046
-16,837
| -74% | -$39K | ﹤0.01% | 13158 |
|
|
2023
Q1 | $55.6K | Sell |
22,883
-39,893
| -64% | -$59.3K | ﹤0.01% | 12022 |
|
|
2022
Q4 | $89.8K | Buy |
62,776
+44,585
| +245% | +$86.9K | ﹤0.01% | 11367 |
|
|
2022
Q3 | $40K | Sell |
18,191
-10,274
| -36% | -$24.8K | ﹤0.01% | 11765 |
|
|
2022
Q2 | $59K | Buy |
28,465
+17,963
| +171% | +$44.4K | ﹤0.01% | 11832 |
|
|
2022
Q1 | $30K | Sell |
10,502
-4,078
| -28% | -$13.1K | ﹤0.01% | 13110 |
|
|
2021
Q4 | $47K | Sell |
14,580
-40,367
| -73% | -$138K | ﹤0.01% | 13284 |
|
|
2021
Q3 | $195K | Sell |
54,947
-18,863
| -26% | -$62.9K | ﹤0.01% | 12023 |
|
|
2021
Q2 | $234K | Buy |
73,810
+29,008
| +65% | +$91.2K | ﹤0.01% | 11824 |
|
|
2021
Q1 | $154K | Buy |
44,802
+17,367
| +63% | +$54K | ﹤0.01% | 11998 |
|
|
2020
Q4 | $69K | Sell |
27,435
-23,613
| -46% | -$51.4K | ﹤0.01% | 10432 |
|
|
2020
Q3 | $107K | Buy |
+51,048
| New | +$121K | ﹤0.01% | 9237 |
|
|
2020
Q2 | – | Sell |
-98,715
| Closed | -$254K | – | 10645 |
|
|
2020
Q1 | $250K | Buy |
98,715
+33,722
| +52% | +$82.8K | ﹤0.01% | 7640 |
|
|
2019
Q4 | $171K | Sell |
64,993
-53,523
| -45% | -$160K | ﹤0.01% | 8291 |
|
|
2019
Q3 | $427K | Buy |
118,516
+31,848
| +37% | +$113K | ﹤0.01% | 7011 |
|
|
2019
Q2 | $292K | Buy |
86,668
+28,920
| +50% | +$102K | ﹤0.01% | 7626 |
|
|
2019
Q1 | $158K | Sell |
57,748
-4,683
| -8% | -$15.3K | ﹤0.01% | 8363 |
|
|
2018
Q4 | $174K | Sell |
62,431
-30,896
| -33% | -$101K | ﹤0.01% | 7969 |
|
|
2018
Q3 | $384K | Sell |
93,327
-2,155
| -2% | -$9.79K | ﹤0.01% | 7150 |
|
|
2018
Q2 | $496K | Sell |
95,482
-2,598
| -3% | -$15.8K | ﹤0.01% | 6385 |
|
|
2018
Q1 | $538K | Buy |
98,080
+41,839
| +74% | +$295K | ﹤0.01% | 5763 |
|
|
2017
Q4 | $458K | Buy |
56,241
+43,678
| +348% | +$417K | ﹤0.01% | 5783 |
|
|
2017
Q3 | $132K | Sell |
12,563
-264
| -2% | -$2.93K | ﹤0.01% | 6932 |
|
|
2017
Q2 | $142K | Sell |
12,827
-396
| -3% | -$3.69K | ﹤0.01% | 6781 |
|
|
2017
Q1 | $111K | Sell |
13,223
-27,008
| -67% | -$190K | ﹤0.01% | 6819 |
|
|
2016
Q4 | $279K | Buy |
40,231
+14,148
| +54% | +$90.3K | ﹤0.01% | 5787 |
|
|
2016
Q3 | $133K | Sell |
26,083
-47,740
| -65% | -$285K | ﹤0.01% | 6537 |
|
|
2016
Q2 | $441K | Sell |
73,823
-2,128
| -3% | -$11.8K | ﹤0.01% | 4669 |
|
|
2016
Q1 | $346K | Buy |
75,951
+17,452
| +30% | +$77.7K | ﹤0.01% | 4903 |
|
|
2015
Q4 | $263K | Buy |
58,499
+45,595
| +353% | +$193K | ﹤0.01% | 5419 |
|
|
2015
Q3 | $41K | Sell |
12,904
-52,897
| -80% | -$160K | ﹤0.01% | 7719 |
|
|
2015
Q2 | $199K | Sell |
65,801
-2,386
| -3% | -$6.71K | ﹤0.01% | 6331 |
|
|
2015
Q1 | $201K | Sell |
68,187
-147,732
| -68% | -$484K | ﹤0.01% | 6175 |
|
|
2014
Q4 | $958K | Buy |
215,919
+37,632
| +21% | +$179K | ﹤0.01% | 3823 |
|
|
2014
Q3 | $918K | Buy |
178,287
+91,697
| +106% | +$489K | ﹤0.01% | 3812 |
|
|
2014
Q2 | $455K | Sell |
86,590
-17,440
| -17% | -$75.4K | ﹤0.01% | 4521 |
|
|
2014
Q1 | $433K | Buy |
104,030
+82,585
| +385% | +$283K | ﹤0.01% | 4560 |
|
|
2013
Q4 | $63K | Buy |
21,445
+8,386
| +64% | +$20.8K | ﹤0.01% | 5913 |
|
|
2013
Q3 | $33K | Buy |
13,059
+2,914
| +29% | +$6.91K | ﹤0.01% | 5990 |
|
|
2013
Q2 | $21K | Buy |
+10,145
| New | +$22.4K | ﹤0.01% | 6048 |
|
Other funds holding ENZ
RC
XT
KCM
GSC
Citadel Advisors's ENZ Position: Q2 2025 in Review
Citadel Advisors sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 210,877 shares — an estimated $78K sold.
Citadel Advisors first reported a position in ENZ in Q2 2013 and held it in 44 quarters. The position peaked at $958K in Q4 2014. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.
- Citadel Advisors reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 210,877 Enzo Biochem, Inc. shares in Q2 2025, an estimated $78K.
- Citadel Advisors first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 44 quarters.
- Citadel Advisors's Enzo Biochem, Inc. position peaked at $958K in Q4 2014.
- 6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.